tiprankstipranks
Trending News
More News >
Immunome (IMNM)
NASDAQ:IMNM
US Market
Advertisement

Immunome (IMNM) AI Stock Analysis

Compare
343 Followers

Top Page

IMNM

Immunome

(NASDAQ:IMNM)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 4o)
Rating:55Neutral
Price Target:
$16.50
▲(5.16% Upside)
Immunome's stock score is primarily influenced by its challenging financial performance, with persistent losses and negative profitability metrics. However, the stock's strong technical indicators suggest bullish momentum, providing a positive offset. The valuation remains unattractive due to negative earnings and no dividend yield, further impacting the overall score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates increasing market acceptance of Immunome's therapies, suggesting potential for long-term expansion and stability in the biotechnology sector.
Cash Flow Improvement
Improving cash generation capabilities enhance Immunome's ability to fund R&D and operational activities, supporting sustained business development and financial health.
Low Leverage
Minimal leverage reduces financial risk, providing Immunome with greater flexibility to invest in growth opportunities and navigate industry challenges without significant debt burden.
Negative Factors
Negative Profitability
Persistent losses impact Immunome's profitability, challenging its ability to achieve sustainable financial performance and potentially limiting reinvestment in growth initiatives.
Operational Inefficiencies
Operational inefficiencies reflected in negative margins may hinder Immunome's capacity to improve profitability, necessitating strategic adjustments to enhance operational effectiveness.
Negative Return on Equity
A negative return on equity indicates significant losses relative to shareholder equity, posing challenges for investor confidence and long-term shareholder value creation.

Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)

Immunome Business Overview & Revenue Model

Company DescriptionImmunome, Inc. (IMNM) is a biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases. Utilizing its proprietary discovery platform, the company identifies and develops therapeutic candidates derived from the immune response of patients. Immunome aims to address unmet medical needs by creating targeted treatments that harness the body's own immune system to combat disease.
How the Company Makes MoneyImmunome generates revenue primarily through the development and commercialization of its therapeutic candidates, which are designed to address specific disease indications. The company may earn income through various streams, including milestone payments from partnerships with pharmaceutical companies, royalties from product sales once therapies are commercialized, and funding from grants or government contracts aimed at supporting research and development efforts. Significant collaborations with larger pharmaceutical companies can also provide upfront payments and additional funding tied to the achievement of development milestones, significantly contributing to the company's financial stability and growth.

Immunome Financial Statement Overview

Summary
Immunome faces substantial financial difficulties, with persistent losses impacting profitability and cash flow. While the balance sheet remains robust due to strong equity, operational inefficiencies need addressing to improve financial health.
Income Statement
45
Neutral
Immunome's income statement reflects significant challenges, with consistent net losses and negative EBIT and EBITDA margins over the periods reported. Despite some revenue growth from 2024 to TTM (Trailing-Twelve-Months), the company operates with negative profitability metrics, indicating ongoing operational difficulties.
Balance Sheet
55
Neutral
The balance sheet shows a strong equity base with a favorable debt-to-equity ratio, suggesting financial stability. However, the company’s high cash position is offset by recurring net losses, which could pressure equity if operations do not improve.
Cash Flow
50
Neutral
Immunome's cash flow statement highlights negative operating cash flows, though financing activities have supported liquidity. Free cash flow is persistently negative, which is concerning for long-term sustainability unless the trend reverses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.59M9.04M14.02M0.000.000.00
Gross Profit12.59M9.04M14.02M-631.00K-755.00K-755.00K
EBITDA-187.92M-151.35M-28.00M-36.27M-23.95M-17.04M
Net Income-212.39M-292.96M-106.81M-37.51M-24.71M-17.84M
Balance Sheet
Total Assets296.29M240.24M148.54M24.05M57.92M44.52M
Cash, Cash Equivalents and Short-Term Investments268.04M217.30M138.14M20.32M49.23M39.77M
Total Debt4.14M4.83M1.65M291.00K317.00K613.00K
Total Liabilities27.02M59.08M28.66M7.39M9.74M3.18M
Stockholders Equity269.27M181.16M119.88M16.65M48.19M41.34M
Cash Flow
Free Cash Flow-186.17M-117.97M-8.40M-28.94M-18.30M-12.72M
Operating Cash Flow-178.68M-110.79M-7.57M-28.69M-18.23M-12.13M
Investing Cash Flow-25.23M-85.06M-30.48M-248.00K-79.00K-586.00K
Financing Cash Flow182.56M240.53M116.41M32.00K27.77M49.94M

Immunome Technical Analysis

Technical Analysis Sentiment
Positive
Last Price15.69
Price Trends
50DMA
11.77
Positive
100DMA
10.71
Positive
200DMA
9.73
Positive
Market Momentum
MACD
1.41
Negative
RSI
66.63
Neutral
STOCH
67.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 15.69 is above the 20-day moving average (MA) of 14.57, above the 50-day MA of 11.77, and above the 200-day MA of 9.73, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 66.63 is Neutral, neither overbought nor oversold. The STOCH value of 67.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Risk Analysis

Immunome disclosed 78 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Immunome Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$1.30B-51.86%-37.09%58.96%
$1.37B-81.20%16.74%59.89%
$1.24B-17.34%83.36%22.27%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
$791.14M-9.66-31.09%11877.28%63.14%
$833.90M-76.09%-42.84%-17.32%
$1.45B-109.12%7.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMNM
Immunome
16.60
4.40
36.07%
GERN
Geron
1.28
-2.98
-69.95%
IMTX
Immatics
10.58
1.22
13.03%
TNGX
Tango Therapeutics
7.77
1.77
29.50%
TSHA
Taysha Gene Therapies
4.88
3.00
159.57%
SANA
Sana Biotechnology
5.25
1.47
38.89%

Immunome Corporate Events

Immunome Advances Cancer Therapy Pipeline Amid Financial Loss
Aug 7, 2025

Immunome, Inc. is a biotechnology company specializing in the development of targeted cancer therapies, with a focus on first-in-class and best-in-class treatments in the oncology sector. The company is advancing a diverse portfolio of therapeutics, including antibody-drug conjugate therapies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025